| Literature DB >> 31621610 |
Yiwen Wu1, Hyun Joo Cho2, Pattamon Panyakaew3, Charulata Sankhla Savant4, Tianxia Wu5, Nguyet Dang6, Mark Hallett7.
Abstract
OBJECTIVE: Melanopsin may be involved in the pathophysiology of photophobia in idiopathic isolated blepharospasm. We assessed the efficacy of blocking wavelengths of melanopsin absorption to reduce blinking in blepharospasm as a possible surrogate for photophobia. <br> METHODS: Twenty-one participants (11 blepharospasm and 10 healthy controls) were studied. There were three sessions: (1) a baseline condition to measure the blink rate (BR) without intervention; (2) two conditions where the participants received intermittent light stimuli with high or low intensity without wearing study lenses; (3) four conditions in which the participants received intermittent light stimuli with high intensity while wearing one of four different lenses: tinted lenses with neutral gray or FL-41, or coated lenses that block 480-nm or 590-nm wavelength. The primary outcome measure was the BR. <br> RESULTS: The blepharospasm group blinked more frequently than controls in dim room conditions. Patients reported greater photosensitivity compared to controls based on the questionnaire and exhibited a higher BR with intermittent light stimuli. The BR decreased for both groups when using 480-nm and 590-nm blocking lenses. In the patients, 480-nm and 590-nm blocking lenses reduced the mean BR by 9.6 blink/min and 10.3 blink/min, respectively, while in the control group, the mean BR decreased by 4.4 blink/min and 4.3 blink/min, respectively. <br> CONCLUSIONS: Blepharospasm patients had increased BR with light stimuli which decreased with 590-nm and 480-nm blocking lenses. The 480-nm- and 590-nm- coated lenses might have therapeutic potential in treating photophobia although BR does not appear to be an optimal biomarker for photophobia. Published by Elsevier Ltd.Entities:
Keywords: Blepharospasm; Blink rate; Dystonia; Photophobia
Mesh:
Substances:
Year: 2019 PMID: 31621610 PMCID: PMC8243242 DOI: 10.1016/j.parkreldis.2019.09.010
Source DB: PubMed Journal: Parkinsonism Relat Disord ISSN: 1353-8020 Impact factor: 4.891